Farouk Mookadam is a Cardiology physician affiliated with University of Arizona. OpenAlex indexes 141 publications with 3,897 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
13400 E Shea Blvd
Scottsdale, AZ 852595452
Telephone
480-301-8000Registry record last updated 13 Mar 2019.
Clinical trials
- Exercise Preconditioning and Breast Cancer Cardiotoxicity
Sponsor: Mayo Clinic
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20242 payments
- PFIZER INC.Program year20241 payment
- Novartis Pharmaceuticals CorporationProgram year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
87.8%Beta blocker31.2%Metoprolol Tartrate59%Metoprolol Succinate22%Carvedilol19%Part D≥51 patientsStatin11.9%Rosuvastatin Calcium78%Atorvastatin Calcium22%Part D<11 patients+ 9 more classes in this area
Blood & clotting
7.2%Factor Xa inhibitor4.6%Eliquis100%Part D<11 patientsP2Y12 inhibitor2.6%Clopidogrel100%Part D<11 patientsAnti-infectives
2.6%Penicillins with extended spectrum2.6%Amoxicillin100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 26-CCC-19392-ACC CHECKPOINT BLOCKED: MULTIMODAL RESCUE OF FULMINANT PEMBROLIZUMAB-INDUCED MYOCARDITIS AND MYASTHENIC CRISIS
Journal of the American College of Cardiology
2026 - A Comprehensive Review of Cardiac Imaging In Mechanical Cardiac Support
Mechanical Circulatory Support
2025 - CARDIOVASCULAR OUTCOMES IN HEAT STROKE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Journal of the American College of Cardiology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Alpert, MD
University of Arizona
Karl Kern, MD
University of Arizona
Peter Reaven, MD
University of Arizona
Alison Stopeck, MD
University of Arizona
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”